EUCTR2014-004119-35-IT进行中（未招募）1 期
Multicentre, prospective, double-blind, in parallel groups, randomized, placebo-controlled clinical trial to evaluate the short-term efficacy and safety of Betamethasone valerate 2.25 mg medicated plaster in patients with chronic lateral epicondylitis (tennis elbow)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.outpatients of both genders, aged =18 years;
- •2.patients suffering from chronic (i.e., for =12 weeks) Lateral Elbow Tendinopathy (MedDRA version 17.0, LLT Classification code: 10024032 = Lateral epicondylitis; 10043258 = Tennis elbow), being confirmed through a clinical diagnosis;
- •3.patients in their symptomatic phase, defined as a pain =50 mm on a 0-100 mm Visual Analogue Scale as perceived when performing a standardized movement (according to Cozen’s or Mill’s test);
- •4.written informed consent to participate in the study obtained according to GCP;
- •5.patients able to comprehend the full nature and the purpose of the study, including possible risks and side effects and patients able to cooperate with the Investigator and to comply with the requirements of the entire study (including ability to attend all the planned study visits according to the time limits), based on Investigator’s judgement;
- •6.female subjects of childbearing potential (i.e., not permanently sterilised - post hysterectomy or tubal ligation status – or not postmenopausal) must be using an appropriate method of contraception according to the definition of Note 3 of ICH M3 Guideline*.
- •*Note: According to the definition of Note 3 of ICH M3 Guideline a highly effective method is defined as those which results in a low failure rate (i.e. less than 1% per year) when used consistently and correctly.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 200
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 200
排除标准
- •1.patients having received a local injection of corticosteroid for their tendinopathy or an intra-articular (any joint) corticosteroid injection <6 months before inclusion, or a local corticosteroid injection for medical conditions other than the one under investigation <1 month before inclusion;
- •2.patients having taken systemic anti-inflammatory steroidal drugs <1 month before inclusion;
- •3.patients having taken systemic NSAIDs (e.g. ibuprofen, ketoprofen) <48 hours (paracetamol permitted), or long-acting NSAIDs (piroxicam or naproxen), opioids and narcotic analgesics <7 days before inclusion, or patients under chronic treatment with topical or systemic analgesics/NSAIDs;
- •4.patients having undergone a standard physiotherapeutic treatment (except for cold or hot patch application and/or use of braces for casting), an electro-medical Tecar therapy, a Laser therapy, Iontophoresis therapy or Eccentric Training for the treatment of their tendinopathy <3 months before inclusion;
- •5.patients presenting signs and symptoms suggestive of another cause for their pain in the affected area (e.g. congenital or acquired structural or neurological abnormalities, chronic joint diseases, possible traumatic or neoplastic origin of symptoms, bilateral complaints);
- •6.patients having undergone a previous surgical treatment in the affected area, or a surgical treatment planned in the 6 weeks following the inclusion;
- •7.patients having fractures, dislocations, calcifications or ruptures of tendon in the affected area;
- •8.patients with history of previous fractures or ruptures of tendon in the affected area;
- •9.patients with systemic musculoskeletal disease or neurological disorder which the Investigator considers to potentially affect the outcome of the study;
- •10.patients with skin lesions or dermatological diseases in the affected area that could interfere with the application of the plaster (e.g. dermatitis, skin ulcers, burns, skin infections, skin atrophy).
- •Additional exclusion criteria will be:
- •11.allergy to the active substance or excipients contained in the tested medication (particularly betamethasone valerate, methyl parahydroxybenzoate and propyl-parahydroxybenzoate) or to the rescue medication (paracetamol);
- •12.history of anaphylaxis to drugs or allergic reactions in general which the Investigator considers to potentially affect the outcome of the study;
- •13.presence of severe cardiac, liver or kidney dysfunction;
- •14.underlying disease or medication that severely compromise the subject's immune system (T-lymphocytes impairment or immunosuppressive therapy) and that, in the view of the Investigator, could compromise the patient’s participation in the study;
- •15.patients with clinically significant or unstable concurrent disease whose sequelae or treatment might interfere with the study evaluation parameters;
- •16.patients with metabolic or other diseases like malignancy and major psychiatric disorders that, in the view of the Investigator, could compromise the patient’s participation in the study;
- •17.patients with history of alcohol or drug abuse (within previous 12 months);
- •18.pregnant or breast-feeding women;
- •19.patients unable to comprehend the full nature and the purpose of the study, including possible risks and side effects and patients unable to cooperate with the Investigator and to comply with the requirement of the entire study (including inability to attend all the planned study visits according to t
研究者
相似试验
进行中（未招募）
不适用
A multicentre, prospective, double-blind, in parallel groups randomised, versus placebo and versus reference product controlled, confirmatory clinical trial of the efficacy and tolerance of Flector Tissugel Heparine in the treatment of ankle sprains. - NDankle sprainsMedDRA version: 9.1Level: LLTClassification code 10023229Term: Joint sprainEUCTR2006-003773-28-ITIBSA420
进行中（未招募）
不适用
A multicentre, prospective, double-blind, in parallel groups randomised, versus placebo and versus reference product controlled, confirmatory clinical trial of the efficacy and tolerance of Flector Tissugel Héparine in the treatment of mild-to-moderate contusions.mild-to-moderate contusionsEUCTR2005-003829-31-DEIBSA Institut Biochimique S.A.330
进行中（未招募）
1 期
A multicentre, prospective, double-blind, in parallel groups randomised, versus placebo and versus reference product controlled, confirmatory clinical trial of the efficacy and tolerance of Flector Tissugel Héparine in the treatment of mild-to-moderate contusions.Muscle contusion with hematoma and pain of upper or lower limbsEUCTR2005-003829-31-CZIBSA, Institut Biochimique S.A.330
已完成
4 期
to study the effect and safety of two products in treatment of psoriasis.CTRI/2012/09/003001Glenmark Pharmaceuticals Limited200
进行中（未招募）
1 期
Phase III study to assess efficacy and safety of D9421-C 9 mg with active Crohn’s Disease in JapaEUCTR2014-004132-20-Outside-EU/EEAAstraZeneca K.K.112